1. Home
  2. DEA vs CTMX Comparison

DEA vs CTMX Comparison

Compare DEA & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Easterly Government Properties Inc.

DEA

Easterly Government Properties Inc.

HOLD

Current Price

$23.27

Market Cap

1.0B

Sector

Real Estate

ML Signal

HOLD

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$4.20

Market Cap

977.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DEA
CTMX
Founded
2011
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
977.1M
IPO Year
2014
2015

Fundamental Metrics

Financial Performance
Metric
DEA
CTMX
Price
$23.27
$4.20
Analyst Decision
Hold
Strong Buy
Analyst Count
5
10
Target Price
$23.49
$12.10
AVG Volume (30 Days)
273.1K
3.8M
Earning Date
04-27-2026
05-08-2026
Dividend Yield
7.77%
N/A
EPS Growth
50.00
N/A
EPS
0.02
N/A
Revenue
$336,099,000.00
$76,201,000.00
Revenue This Year
$5.41
N/A
Revenue Next Year
$3.33
$7.61
P/E Ratio
$1,177.50
$22.58
Revenue Growth
11.27
N/A
52 Week Low
$19.82
$0.90
52 Week High
$24.94
$8.21

Technical Indicators

Market Signals
Indicator
DEA
CTMX
Relative Strength Index (RSI) 53.14 42.10
Support Level $22.99 $4.02
Resistance Level $23.74 $4.33
Average True Range (ATR) 0.43 0.27
MACD 0.00 -0.03
Stochastic Oscillator 17.93 16.97

Price Performance

Historical Comparison
DEA
CTMX

About DEA Easterly Government Properties Inc.

Easterly Government Properties Inc is a real estate investment trust. The company is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. It generates all its revenue by leasing its properties to such agencies. The company operates in single segment for the purposes of assessing performance and making operating decisions.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: